CNBC July 17, 2023
Key Points
– Nirsevimab is the first shot approved by the FDA to protect all infants against RSV regardless of whether they are healthy or have a medical condition.
– Nirsevimab is administered either before or during an infant’s first RSV season.
– RSV is the leading cause of hospitalization among children less than a year old, according to scientists.
The Food and Drug Administration on Monday approved AstraZeneca and Sanofi‘s shot that protects infants and toddlers against respiratory syncytial virus, which is the leading cause of hospitalization among babies in the U.S.
Nirsevimab is the first shot approved by the FDA to protect all infants against RSV regardless of whether they are healthy or have a medical condition.
The...
Today's Sponsors
Today's Sponsor